Xenikos
Molenveldlaan 168
Nijmegen
6523RN
Tel: 31-24-300-01-00
Fax: 31-84-741-07-35
Website: http://www.xenikos.com/
18 articles with Xenikos
-
Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover's homologous booster against Omicron increases antibodies, and much more.
-
Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
6/27/2022
Xenikos B.V. today announced enrollment of the first patient in a global pivotal Phase 3 clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT).
-
Xenikos Appoints Hassan Aly, MD, PhD as Chief Medical Officer
9/22/2021
Xenikos B.V. today announced the appointment of Hassan Aly, MD, PhD, as Chief Medical Officer.
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
9/8/2021
Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced the closing of €40 million in convertible debt consisting of two equal tranches of €20 million.
-
Clinical Catch-Up: July 19-23
7/26/2021
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more. -
Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
7/19/2021
Xenikos B.V. announced that it has reached agreement with the US Food and Drug Administration and the European Medicines Agency on the design of its pivotal randomized Phase 3 clinical study to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplant.
-
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial
12/18/2019
Xenikos B.V. announced that the first patient has been treated in their U.S.-based Phase 3 registration trial designed to evaluate the use of T-Guard for treating steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
-
Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting
12/9/2019
The Dutch company Xenikos B.V., which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, reports data from an expanded access program using T-Guard to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
-
Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer
12/2/2019
Experienced financial leader joins Xenikos as they enter the final stage of clinical development of T-Guard®
-
Xenikos receives FDA Fast Track designation for T-Guard® for treating steroid-refractory acute graft-versus-host disease
10/14/2019
The Dutch company Xenikos B.V. announced that the U.S. Food and Drug Administration has granted Fast Track designation to T-Guard, Xenikos’ flagship product designed to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
-
Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD
6/11/2019
The Dutch company Xenikos B.V. announced that the U.S. Food and Drug Administration has approved an investigational new drug application to initiate a U.S.-based clinical Phase 3 registration trial in order to test the efficacy of T-Guard for treating steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.
-
Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard® in acute graft-versus-host disease
12/20/2018
Study will be conducted at up to 20 leading transplant centers in the U.S.
-
Final results from T-Guard® Phase 1/2 trial in steroid-resistant acute graft-versus-host disease published online in peer-reviewed journal Biology of Blood and Marrow Transplantation
11/16/2018
Overall response rate at 28 days of 60%, complete response rate of 50%
-
Xenikos Announces Data From Phase I/II Trial With T-Guard for Treatment of Steroid-Resistant Acute GVHD Presented at ASH Annual Meeting
12/11/2017
Treatment with a short course of T-Guard was generally well tolerated with no significant infusion reactions.
-
Xenikos Appoints Eric Van Hooren As Chief Development Officer To Drive Forward T-Guardtm Clinical Development Program
11/2/2016
-
Xenikos To Participate In 3PBio Forum Technology Transfer Panel On September 29 At BIOSPAIN 2016
9/20/2016
-
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease
9/15/2016
-
Xenikos To Introduce Immunotherapy T-Guard To Potential Pharmaceutical Partners At BIO International Convention 2016
5/24/2016